Intrinsic Activating Properties of GP IIb/IIIa Blockers

Thrombosis Research

Volumn 103, Issue SUPPL. 1, 2001, Pages

  Peter, Karlheinz ^a   Schwarz, Meike ^a   Nordt, Thomas ^a   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Abciximab; Eptifibatide; GP IIb IIIa blockers; Intrinsic activating property; Thrombocytopenia; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; INTEGRIN; LIGAND; ORBOFIBAN;

ARTICLE; DRUG EFFECT; DRUG INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES, MONOCLONAL; HUMANS; OLIGOPEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING;

EID: 0035975625     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00300-0     Document Type: Article

References (50)

1. Platelet GPIIb-IIIa blockers
2. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
3. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
4. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events
5. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
6. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
7. Identification of membrane proteins mediating the interaction of human platelets
8. The platelet membrane glycoprotein IIb-IIIa complex
9. Platelet integrin GPIIb/IIIa: Structure-function correlations. An update and lessons from other integrins
10. Platelet glycoprotein IIb. Chromosomal localization and tissue expression
11. Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17
12. Heriditaere haemorrhagische thrombasthenie: Ein beitrag zur pathologie der blutplaettchen
13. Specific roles for platelet surface glycoproteins in platelet function
14. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins
15. Integrins: A family of cell surface receptors
16. Adhesion receptors of the immune system
17. Integrins: Versatility, modulation and signalling in cell adhesion
18. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion
19. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers
20. Monoclonal antibodies to ligand-occupied conformers of integrin ∀IIbβ3 (glycoprotein IIb-IIIa) alters receptor affinity, specificity and function
21. Evaluation of platelet membrane glycoproteins in coronary artery disease: Consequences for diagnosis and therapy
22. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: Discriminating abciximab and small molecular weight antagonists
23. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit
24. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor
25. Focal adhesions: A nexus for intracellular signaling and cytoskeletal dynamics
26. 2 (LFA-1,CD11a/CD18) cytoplasmic domain/cytoskeleton interaction
27. Cell adhesion to fibronectin and tenascin: Quantitative measurements of initial binding and subsequent strengthening response
28. Micromanipulation of adhesion of phorbol 12-myristate-13-acetate-stimulated T lymphocytes to planar membranes containing intercellular adhesion molecule-1
29. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor
30. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo
31. Ligands "activate" integrin ∀IIbβ3 (platelet GP IIb-IIIa)
32. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (∀IIb∃3) inhibitors
33. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
34. Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations
35. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
36. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
37. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development
38. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) Trial
39. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
40. Participation of tyrosine phosphorylation in cytoskeletal reorganization, ∀IIbβ3 integrin receptor activation and aspirin-insensitive mechanisms of thrombin-stimulated human platelets
41. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction
42. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
43. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling
44. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
45. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
46. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
47. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
48. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors?
49. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
50. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia